What Transformation Has the Epigenetics Market Undergone?
The epigenetics market has seen considerable growth due to a variety of factors.
• In recent times, the scale of the epigenetics market has expanded significantly. It is projected to rise from a $10.65 billion in 2024 to $12.83 billion in 2025, with a compound annual growth rate (CAGR) of 20.4%.
Factors such as heightened research funding, an uptick in chronic disease occurrences, personalized medicine, cancer research, and an aging population have contributed to this notable growth in the historic period.
How Will The Epigenetics Market Size Evolve In The Foreseeable Future?
The epigenetics market is expected to maintain its strong growth trajectory in upcoming years.
• An explosive increase is foreseen in the size of the epigenetics market in the coming years. The market value is anticipated to rise to $29.08 billion by 2029, with a compound annual growth rate (CAGR) of 22.7%.
Factors contributing to this growth during the forecasted period include developments in epigenetic drugs, the role of epigenetics in environmental health and precision agriculture, regulatory backing, patient awareness, and advocacy efforts. The period is also expected to witness major trends like epitranscriptomics, single-cell epigenomics, epigenetic editing, epigenetic biomarkers, research in aging and longevity, and interactions between microbiome and epigenome.
What Are The Essential Drivers Behind The Growth Of The Epigenetics Market?
The escalating incidences of cancer and other illnesses are considerably fuelling the expansion of the epigenetics market. As the rate of these diseases rise, so does the need for epigenetics. For example, the National Cancer Institute (NCI), a US-based government entity, reported close to 20 million fresh cancer cases in 2022, culminating in roughly 9.7 million cancer-related deaths. This forecast suggests that by 2040, annual cancer cases will rise to 29.9 million and cancer-associated deaths will escalate to 15.3 million. Moreover, the Centers for Disease Control and Prevention (CDC) estimate that roughly 659,000 individuals in the USA die from heart disease annually. The escalating incidence of cancer and similar illnesses necessitates testing and understanding the alterations in the genes, inevitably leading to an increased application and need for epigenetics. Therefore, the rising rates of cancer and other diseases are set to propel the epigenetics market into greater heights in future years.
How Is The Global Epigenetics Market Divided Into Key Segments?
The epigenetics market covered in this report is segmented –
1) By Product: Reagents, Enzymes, Instruments, Kits
2) By Technology: DNA Methylation, Histone Methylation, Histone Acetylation, Large Noncoding RNA, MicroRNA Modification, Chromatin Structures
3) By Application: Oncology, Metabolic Diseases, Developmental Biology, Immunology, Cardiovascular Diseases, Other Applications
4) By End-User: Academic And Research Institutes, Pharmaceutical And Biotechnology Companies, Contract Research Organizations, Other End Users
Subsegments:
1) By Reagents: DNA Methylation Reagents, Histone Modification Reagents, RNA Modifications Reagents, Enzymes
2) By Enzymes: DNA Methyltransferases, Histone Acetyltransferases, Histone Deacetylases, Other Epigenetic Enzymes
3) By Instruments: Sequencers, PCR Machines, Microarray Platforms, Mass Spectrometers
4) By Kits: DNA Methylation Kits, Chromatin Immunoprecipitation (ChIP) Kits, RNA-Seq Kits, Bisulfite Conversion Kits
Pre-Book The Epigenetics Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Reshaping The Future Of The Overview Market?
A major focus for key players in the epigenetics market is creating highly advanced technological solutions, such as DNA sequencing methods. These methods not only enhance precision medicine but also contribute to a more thorough understanding and improved treatment of diseases. DNA sequencing methods are tools which identify the sequence of nucleotides within a DNA molecule, providing a high level of genetic analysis. This data is essential in pinpointing genetic variations linked to disease, thus furthering the field of precision medicine. For instance, US-based biotech firm, Illumina Inc., unveiled the Illumina Complete Long Read Technology in March 2023. This technology allows for both long-read and short-read sequencing within one instrument, greatly improving versatility in the realm of genomic research. It not only reduces DNA input requirements but also optimizes the workflow, simplifying the library preparation process, particularly for more complex samples. This technology maintains high accuracy when identifying variants, generating reliable data crucial for complete genomic analysis.
Who Are the Key Players in the Epigenetics Market?
Major companies operating in the epigenetics market include:
• Illumina Inc.
• Thermo Fisher Scientific
• Merck Millipore
• Active Motif
• Abcam PLC
• Qiagen NV
• Diagenode SA
• CellCentric Ltd.
• Chroma Medicine Inc.
• Constellation Pharmaceuticals Inc.
• Domainex Ltd.
• Eisai Co. Ltd.
• Epigen Biosciences Inc.
• EpigenDx Inc.
• Epigenomics AG
• Epizyme Inc.
• Gilead Sciences Inc.
• GlaxoSmithKline plc
• Janssen Pharmaceuticals Inc.
• Locus Biosciences Inc.
• MDxHealth SA
• Novartis AG
• OncoDNA SA
• Oryzon Genomics S.A.
• Pfizer Inc.
• Syndax Pharmaceuticals Inc.
• Valirx plc
What are the Regional Insights into the Epigenetics Market?
North America was the largest region in the epigenetics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the epigenetics market during the forecast period. The regions covered in the epigenetics market report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
